Integrated Advisors Network LLC cut its position in Johnson & Johnson (NYSE:JNJ) by 4.9% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 35,642 shares of the company’s stock after selling 1,854 shares during the quarter. Integrated Advisors Network LLC’s holdings in Johnson & Johnson were worth $5,306,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds have also recently made changes to their positions in the company. Newfound Research LLC purchased a new position in shares of Johnson & Johnson in the third quarter valued at $28,000. Islay Capital Management LLC acquired a new stake in Johnson & Johnson in the second quarter valued at $42,000. FAI Wealth Management raised its holdings in Johnson & Johnson by 45.9% in the second quarter. FAI Wealth Management now owns 321 shares of the company’s stock valued at $45,000 after acquiring an additional 101 shares in the last quarter. SeaBridge Investment Advisors LLC raised its holdings in Johnson & Johnson by 160.0% in the second quarter. SeaBridge Investment Advisors LLC now owns 325 shares of the company’s stock valued at $46,000 after acquiring an additional 200 shares in the last quarter. Finally, Crewe Advisors LLC raised its holdings in Johnson & Johnson by 909.1% in the third quarter. Crewe Advisors LLC now owns 333 shares of the company’s stock valued at $50,000 after acquiring an additional 300 shares in the last quarter. Institutional investors and hedge funds own 67.44% of the company’s stock.
JNJ has been the topic of several recent analyst reports. Cantor Fitzgerald upped their price target on shares of Johnson & Johnson from $168.00 to $180.00 and gave the company an “overweight” rating in a report on Wednesday, October 14th. Credit Suisse Group upped their price target on shares of Johnson & Johnson from $163.00 to $168.00 and gave the company an “outperform” rating in a report on Wednesday, October 14th. Raymond James reaffirmed a “buy” rating on shares of Johnson & Johnson in a report on Friday. Stifel Nicolaus cut shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Wednesday, August 19th. Finally, ValuEngine raised shares of Johnson & Johnson from a “sell” rating to a “hold” rating in a report on Monday, August 3rd. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and ten have given a buy rating to the company’s stock. Johnson & Johnson presently has a consensus rating of “Buy” and a consensus price target of $164.93.
JNJ stock opened at $146.36 on Friday. The company has a quick ratio of 1.24, a current ratio of 1.48 and a debt-to-equity ratio of 0.51. Johnson & Johnson has a fifty-two week low of $109.16 and a fifty-two week high of $157.00. The firm’s 50-day simple moving average is $145.51 and its 200 day simple moving average is $146.57. The stock has a market cap of $385.30 billion, a PE ratio of 23.01, a price-to-earnings-growth ratio of 3.04 and a beta of 0.69.
Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Sunday, October 18th. The company reported $2.20 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.98 by $0.22. The business had revenue of $21.08 billion during the quarter, compared to analyst estimates of $20.15 billion. Johnson & Johnson had a return on equity of 34.64% and a net margin of 21.01%. Johnson & Johnson’s quarterly revenue was up 1.7% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.12 EPS. Equities analysts forecast that Johnson & Johnson will post 7.99 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be issued a $1.01 dividend. This represents a $4.04 dividend on an annualized basis and a yield of 2.76%. The ex-dividend date is Monday, November 23rd. Johnson & Johnson’s dividend payout ratio is 46.54%.
In other news, EVP Kathryn E. Wengel sold 16,115 shares of the stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $153.52, for a total transaction of $2,473,974.80. Following the sale, the executive vice president now directly owns 66,658 shares of the company’s stock, valued at approximately $10,233,336.16. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Corporate insiders own 0.27% of the company’s stock.
About Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DR.
Further Reading: Trading Ex-Dividend
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.